PDL BioPharma: EKR Therapeutics and PDL BioPharma Sign Asset Purchase Agreement for Cardiovascular Products
CEDAR KNOLLS, NJ and REDWOOD CITY, CA (MARKET WIRE) EKR Therapeutics, Inc. and PDL BioPharma, Inc. (NASDAQ: PDLI) today announced that they have entered into an agreement under which EKR would acquire the rights to PDL's cardiovascular products, consisting of Cardene(R) I.V. (nicardipine hydrochloride), Cardene SR(R) and new formulations of Cardene in development, as well as Retavase(R) (reteplase) and the development product ularitide. Under the terms of the agreement, PDL would receive cash payments of $85 million at closing, up to an additional $85 million in development and sales milestones for the new Cardene formulations, as well as (Source: Market Wire - Pharmaceuticals and Biotech)div id=medwormpbiMedWorm Message:/i/b Please support the a href=http://www.doctorsinchains.org/ target=_blankDoctors In Chains/a campaign for the a href=http://www.doctorsinchains.org/medics/a tortured and sentenced for up to 15 years in a href=http://www.doctorsinchains.org/Bahrain/a. a href=https://twitter.com/#!/search/%23FreeDoctors#FreeDoctors/a/p/div

Cardene Sr(Nicardipine Hydrochloride) Capsule, Gelatin Coated [PDL BioPharma, Inc.]
Updated Date: May 22, 2008 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))